TW200744670A - Methods for the treatment of macular degeneration and related eye conditions - Google Patents

Methods for the treatment of macular degeneration and related eye conditions

Info

Publication number
TW200744670A
TW200744670A TW096106212A TW96106212A TW200744670A TW 200744670 A TW200744670 A TW 200744670A TW 096106212 A TW096106212 A TW 096106212A TW 96106212 A TW96106212 A TW 96106212A TW 200744670 A TW200744670 A TW 200744670A
Authority
TW
Taiwan
Prior art keywords
macular degeneration
treatment
methods
eye conditions
related eye
Prior art date
Application number
TW096106212A
Other languages
Chinese (zh)
Inventor
Milton Lethan Pressler
William Sasiela
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200744670A publication Critical patent/TW200744670A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides unilamellar vesicles comprised of phospholipids for preventing and treating age-related macular degeneration and related conditions. The compositions and methods of the instant invention encompass a novel approach to the treatment of age-related macular degeneration and related conditions. Pharmaceutical compositions for this use are also provided.
TW096106212A 2006-02-21 2007-02-16 Methods for the treatment of macular degeneration and related eye conditions TW200744670A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77552006P 2006-02-21 2006-02-21

Publications (1)

Publication Number Publication Date
TW200744670A true TW200744670A (en) 2007-12-16

Family

ID=38226652

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096106212A TW200744670A (en) 2006-02-21 2007-02-16 Methods for the treatment of macular degeneration and related eye conditions

Country Status (4)

Country Link
JP (1) JP2007224032A (en)
AR (1) AR059581A1 (en)
TW (1) TW200744670A (en)
WO (1) WO2007096744A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5514098B2 (en) 2008-02-29 2014-06-04 公益財団法人名古屋産業科学研究所 Lips for reaching the posterior segment and pharmaceutical compositions for posterior segment diseases
SG10201913375YA (en) * 2016-04-19 2020-02-27 Univ Nanyang Tech Subconjuctival depot forming formulations for ocular drug delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141018A1 (en) * 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Use of negatively charged phospholipids and compositions comprising phospholipids for the treatment of the eye
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
CA2622475A1 (en) * 2005-09-26 2007-04-05 Vasogen Ireland Limited Treatment of inflammation and vascular abnormalities of the eye

Also Published As

Publication number Publication date
AR059581A1 (en) 2008-04-16
JP2007224032A (en) 2007-09-06
WO2007096744A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
TN2013000275A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
CY1116062T1 (en) PREVENTIVE AND THERAPEUTIC EDUCATION OF SUPPLEMENTAL EYE DISEASES
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
ATE510538T1 (en) COMPOSITIONS AND METHODS FOR NERVE PROTECTION
MY155320A (en) Alkoxy compounds for disease treatment
MX2009009738A (en) Treatment of age-related macular degeneration using inhibitors of complement factor d.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
JO3065B1 (en) Compounds and compositions as tlr activity modulators
MX343688B (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same.
ZA200809493B (en) Method of treatment of age-related macular degeneration (AMD)
EA201270018A1 (en) Opsync ligands, compositions and methods of use
MX2009010059A (en) Quinoline derivatives for the treatment of inflammatory diseases.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2009009636A (en) Methods of treating ophthalmic diseases.
MX2010000351A (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders.
MX2012001134A (en) Compositions and methods for inhibition of the jak pathway.
EA200900582A1 (en) PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF EYE PATHOLOGIES
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
EA201190337A1 (en) METHOD OF TREATMENT
WO2008063808A3 (en) Encapsulated peptide amphiphile nanostructures
EP1885371A4 (en) Therapeutic compositions and methods
MX2014005209A (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent.
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
EP2083841A4 (en) Treatment for age-related macular degeneration and other diseases of the eye